President Trump is Bringing Drug
Manufacturing Back
President
Donald J. Trump is determined to make the American pharmaceutical and biotechnology
industries great again — both as a matter of national security and to unleash unprecedented
prosperity for American workers.
Gilead Sciences
became the latest industry leader to announce a massive new investment in its U.S.
operations with an $11 billion boost to its planned
U.S.-based spending.
The
company joins a host of others in expanding their domestic footprint to align
with President Trump’s vision:
·
New Jersey-based
Johnson & Johnson announced a $55 billion investment in manufacturing,
research and development, and technology.
·
Roche, a Swiss drug and diagnostics company, announced a
$50 billion investment in its U.S.-based manufacturing and research and development.
·
New Jersey-based
Bristol Myers Squibb announced a $40 billion investment in research, development,
technology, and manufacturing.
·
Indiana-based
Eli Lilly and Company announced a $27 billion
investment to more than double its domestic manufacturing capacity.
·
Novartis, a Swiss drugmaker, announced a $23 billion
investment to build or expand ten manufacturing facilities across the U.S.
·
Illinois-based
AbbVie announced a $10 billion
investment over the next ten years to support volume growth and add four new manufacturing
plants to its network.
·
New Jersey-based
Merck & Co. announced it will invest
a total of $9 billion over the next several years after opening a new $1 billion
North Carolina manufacturing facility — including a new state-of-the-art
biologics manufacturing plant in Delaware.
o
Merck
Animal Health announced an $895 million
investment to expand their manufacturing operation in Kansas.
·
New York-based
Regeneron Pharmaceuticals announced a $3 billion
agreement with FUJIFILM Diosynth Biotechnologies to produce
drugs at its North Carolina facility.
·
California-based
Amgen announced a $900 million investment in its Ohio-based manufacturing
operation.
·
Illinois-based
Abbott Laboratories announced a $500 million investment in its Illinois and
Texas facilities.